- Reaction score
- 1,701
Evidence does not support the use of cannabidiol (CBD) products as a treatment for chronic pain, a new review found.
A meta-analysis of relevant studies published in scientific journals found a lack of convincing evidence that CBD – packaged as oils, vapes, creams, gummies, drinks, and more – reduces pain, prompting the team of UK and Canadian researchers to advise caution when comparing the marketing claims of CBD products.
Scientists were still learning about the potential benefits and risks of CBD when its promotion as a pain reliever took off with a substantial head start.
The authors hope more balanced, evidence-based advice can now be given to patients and their care providers, while research focuses on effective pain treatments.
Seems like this article is giving a lot of weight to this one study. I suspect there might be some possible bias in this research just by the tone of the article above. I suspect it might have been funded by some pro pharma companies.
A meta-analysis of relevant studies published in scientific journals found a lack of convincing evidence that CBD – packaged as oils, vapes, creams, gummies, drinks, and more – reduces pain, prompting the team of UK and Canadian researchers to advise caution when comparing the marketing claims of CBD products.
Scientists were still learning about the potential benefits and risks of CBD when its promotion as a pain reliever took off with a substantial head start.
The authors hope more balanced, evidence-based advice can now be given to patients and their care providers, while research focuses on effective pain treatments.
Large Review Finds CBD Products Don't Relieve Chronic Pain After All
Evidence does not support the use of cannabidiol (CBD) products as a treatment for chronic pain, a new review found.
www.sciencealert.com
Seems like this article is giving a lot of weight to this one study. I suspect there might be some possible bias in this research just by the tone of the article above. I suspect it might have been funded by some pro pharma companies.